









市场行情
/
股票
/
nasdaq-vyne
/

Vyne Therapeutics Inc

VYNE

0.586USD

+0.001+0.21%

收盘 12/19, 16:00（美东）报价延迟15分钟

18.62M总市值

亏损市盈率 TTM



Vyne Therapeutics Inc

0.586

+0.001+0.21%

概览公司财务分析

概览

公司

财务

分析

关于 Vyne Therapeutics Inc 公司

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Vyne Therapeutics Inc简介



公司代码VYNE

公司名称Vyne Therapeutics Inc

上市日期Jan 25, 2018

CEODomzalski (David)

员工数量13

证券类型Ordinary Share

年结日Jan 25

公司地址685 Route 202/206 N., Suite 301

城市BRIDGEWATER

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编08807

电话18007757936

网址https://vynetherapeutics.com/

公司代码VYNE

上市日期Jan 25, 2018

CEODomzalski (David)

Vyne Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

112.77K

-2.94%

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

54.74K

+41.39%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

44.30K

+57.33%

Mr. Steven L. Basta

Independent Director

7.45K

Ms. Sharon Barbari

Independent Director

Mr. David Domzalski

President, Chief Executive Officer, Director

Ms. Elisabeth A. Sandoval Little

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

112.77K

-2.94%

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

54.74K

+41.39%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

44.30K

+57.33%

Mr. Steven L. Basta

Independent Director

7.45K

Ms. Sharon Barbari

Independent Director

收入明细

单位: USD更新时间: 10月6日周一

FY2024

FY2023

FY2022

FY2021

FY2020

业务USD

名称

营收

占比

Royalty revenues

501.00K

0.00%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Royalty revenues

501.00K

0.00%

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

Access Industries, Inc.

3.35%

Baker Bros. Advisors LP

2.56%

Delaware Street Capital, L.L.C.

2.09%

Acorn Capital Advisors, LLC

1.76%

Shay Capital LLC

1.48%

其他

88.75%

持股股东

占比

Access Industries, Inc.

3.35%

Baker Bros. Advisors LP

2.56%

Delaware Street Capital, L.L.C.

2.09%

Acorn Capital Advisors, LLC

1.76%

Shay Capital LLC

1.48%

其他

88.75%

股东类型

持股股东

占比

Hedge Fund

8.41%

Corporation

3.35%

Investment Advisor

2.99%

Investment Advisor/Hedge Fund

2.19%

Individual Investor

1.31%

Research Firm

0.45%

其他

81.29%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

8.51M

25.77%

-898.65K

2025Q2

9.46M

56.76%

-1.30M

2025Q1

9.36M

56.20%

-1.38M

2024Q4

9.37M

63.49%

-533.87K

2024Q3

8.98M

61.30%

-594.32K

2024Q2

9.65M

66.73%

+287.65K

2024Q1

9.64M

67.66%

+101.95K

2023Q4

101

10.22M

72.71%

+4.63M

2023Q3

117

471.27K

14.37%

-340.06K

2023Q2

135

501.83K

15.37%

-314.68K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Access Industries, Inc.

1.12M

4.38%

Feb 14, 2025

Delaware Street Capital, L.L.C.

696.47K

2.73%

Sep 30, 2024

Acorn Capital Advisors, LLC

736.57K

2.89%

-49.37K

-6.28%

Jun 30, 2025

Ikarian Capital LLC

290.00K

1.14%

+290.00K

Jun 30, 2025

The Vanguard Group, Inc.

496.30K

1.95%

+20.65K

+4.34%

Jun 30, 2025

Domzalski (David T)

107.13K

0.42%

-12.68K

-10.58%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

公告日期

类型

比率

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

常见问题

Vyne Therapeutics Inc的前五大股东是谁？



Vyne Therapeutics Inc 的前五大股东如下：
Access Industries, Inc.持有股份：1.12M，占总股份比例：4.38%。
Delaware Street Capital, L.L.C.持有股份：696.47K，占总股份比例：2.73%。
Acorn Capital Advisors, LLC持有股份：736.57K，占总股份比例：2.89%。
Ikarian Capital LLC持有股份：290.00K，占总股份比例：1.14%。
The Vanguard Group, Inc.持有股份：496.30K，占总股份比例：1.95%。